Join
Live feed
·
PRReleasevia Quantisnow
Belite Bio Inc logo

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

ByQuantisnow·Wall Street's wire, on your screen.
BLTE· Belite Bio Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BLTE (Belite Bio Inc) and more on Quantisnow.